Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
Acambis plc |
Sanofi Pasteur (France) |
Agreement to license a single dose vaccine, ChimeriVax, for Japanese encephalitis |
Deal could be worth nearly $40M; Sanofi Pasteur gains marketing, distribution and certain manufacturing rights worldwide, excluding India and the Indian subcontinent, and the U.S., for which Sanofi Pasteur has an option (2/14) |
Affectis |
Dalton Pharma Services (Canada) |
Contract services agreement for the manufacturing of preclinical tox materials |
The agreement relates to the company's P2X7 antidepressant candidate (3/1) |
Barrier |
Novartis Consumer Health (unit of Novartis AG; Switzerland) |
Agreement under which Novartis will promote Barrier's Vusion ointment to pediatricians |
The treatment is for diaper dermatitis complicated by documented candidiasis in infants and children four weeks and older (3/6) |
Bioxel |
Undisclosed medical device company |
Bioxel exclusively will supply paclitaxel to the company, which specializes in coated stents |
The three-year, renewable agreement provides for paclitaxel supplies from development through commercialization; terms were not disclosed (3/14) |
Cangene |
Apotex Corp. (Canada) |
Apotex signed a five-year deal with Novation LLC for distribution of Cangene's hepatitis B hyperimmune product, HepaGam B |
Apotex is the U.S. distributor for HepaGam B; the product is a hepatitis B immune globulin injection; terms were not disclosed (3/13) |
Critical |
DEY LP (affiliate of Merck KGaA; Germany) |
Co-promotion agreement on products targeting the U.S. respiratory care market |
They will jointly promote Critical's marketed asthma drug, Zyflo, and, if approved, a controlled-release formulation of the product; also, Critical would co-promote DEY's chronic obstructive pulmonary disease agent; the latter two products are under FDA review (3/14) |
Dendritic Nano- |
EMD Biosciences (division of Merck KGaA) based on Priostar dendrimers for the DNA and siRNA transfection research markets |
Worldwide, exclusive license and supply agreement for Priofect transfection reagents |
Financial terms were not disclosed (2/20) |
Galapagos NV |
Johnson & Johnson Pharmaceutical Research & Development |
Agreement for Galapagos' BioFocus DPI service division to supply small- molecule compounds for drug discovery to J&J |
Financial terms were not disclosed; the two-year supply agreement expands an existing drug-discovery relationship (3/8) |
Jazz |
Solvay Pharmaceuticals Inc. |
Marketing rights agreement for Luvox tablets, as well as fluvoxamine maleate extended- release capsules in the U.S., upon FDA approval |
The capsules are under regulatory review in obsessive compulsive disorder and generalized social anxiety disorder in adults; Jazz made an up-front payment and will pay Solvay regulatory and sales milestones, plus royalties (2/1) |
Orphan Europe |
Jazz Pharmaceuticals Inc. |
Worldwide rights agreement for Cystadane, which is approved in the U.S., Canada, Australia, Israel and Europe |
Cystadane is indicated for the treatment of homocystinuria (3/7) |
QLT Inc. |
TAP Pharmaceutical Products Inc. |
Agreement in which TAP granted a nonexclusive, perpetual, royalty-free |
The deal is part of a $157.5M settlement of a 2003 patent infringement suit filed by TAP (2/9) |
United |
Mochida Pharmaceutical Co. Ltd.(Japan) |
Agreement for the exclusive distribution in Japan of Remodulin injection administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension |
Mochida will be responsible for obtaining marketing authorization (3/28) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; TSX = Toronto Stock Exchange. | |||
